Non-small-cell lung cancer
C Gridelli, A Rossi, DP Carbone, J Guarize… - Nature reviews Disease …, 2015 - nature.com
Lung cancer is one of the most frequently diagnosed cancers and is the leading cause of
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …
cancer-related death worldwide. Non-small-cell lung cancer (NSCLC), a heterogeneous …
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Y Wang, G Schmid-Bindert… - Therapeutic advances in …, 2012 - journals.sagepub.com
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed …
LG Paz-Ares, F de Marinis, M Dediu… - Journal of clinical …, 2013 - ascopubs.org
Purpose In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy
reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI …
reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62; 95% CI …
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine …
M Pérol, C Chouaid, D Pérol, F Barlési… - Journal of Clinical …, 2012 - ascopubs.org
Purpose This phase III study investigated whether continuation maintenance with
gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with …
gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with …
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre …
L Zhang, S Ma, X Song, B Han, Y Cheng… - The lancet …, 2012 - thelancet.com
Background Maintenance treatment of patients with advanced non-small-cell lung cancer
(NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing …
(NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing …
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology …
AP Abernethy, A Arunachalam, T Burke, C McKay… - PloS one, 2017 - journals.plos.org
Purpose To establish a baseline for care and overall survival (OS) based upon
contemporary first-line treatments prescribed in the era before the introduction of immune …
contemporary first-line treatments prescribed in the era before the introduction of immune …
Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?
Background: The current oncologic management of non–small cell lung cancer (NSCLC)
requires pathologic differentiation between adenocarcinoma and squamous cell carcinoma …
requires pathologic differentiation between adenocarcinoma and squamous cell carcinoma …
[HTML][HTML] Epidermal growth factor receptor inhibition in lung cancer: status 2012
Lung cancer is the most common cause of cancer deaths. Most patients present with
advanced-stage disease, and the prognosis is generally poor. However, with the …
advanced-stage disease, and the prognosis is generally poor. However, with the …
Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis
CJ Ensslin, AC Rosen, S Wu, ME Lacouture - Journal of the American …, 2013 - Elsevier
Background Pruritus has been anecdotally described in association with targeted cancer
therapies. The risk of pruritus has not been systematically ascertained. Objective A …
therapies. The risk of pruritus has not been systematically ascertained. Objective A …
Tumor control versus adverse events with targeted anticancer therapies
DMK Keefe, EH Bateman - Nature reviews Clinical oncology, 2012 - nature.com
The advent of targeted anticancer therapies over the past few decades has reinvigorated the
field of cancer therapeutics, with the promise of increased cancer cure rates accompanied …
field of cancer therapeutics, with the promise of increased cancer cure rates accompanied …